M&A related: KYAK +25.6% (KAYAK to be acquired by Priceline for $40/share), BBY +0.5% (Reuters discusses that Schulze's BBY bid may be below $8 bln, according to reports), .
Other news: AGEN +17.6% (announces efficacy shown with GlaxoSmithKline's Phase 3 malaria vaccine candidate, which contains Agenus' Qs-21 Stimulon ADJUVANT), OWW +10.8% (following KYAK/PCLN news), PSTI +5.3% (comments on article published on Bloomberg; submitted a direct request to Bloomberg to publish a correction), CLSN +4.1% (Announces Phase III HEAT Study of ThermoDox in Primary Liver Cancer reaches tgt number of events for unblinding; expects to report top line data in January 2013), ASML +1.4% (still checking), ABT +1.3% (announces consideration for debt tender offers), NFLX +0.6% (Icahn on CNBC says the thought of going hostile on NFLX has crossed his mind, but he doesn't think he'd get it... Says a synergistic buyer could pay a much bigger premium).
Analyst comments: POZN +5.3% (ticking higher, POZEN upgraded to Strong Buy at Ascendiant Capital Markets)
Gapping down: In reaction to disappointing earnings/guidance: GRPN -15.8% (also downgraded at Morgan Stanley, downgraded to Mkt Perform at Barrington Research), MTG -11.3% (ticking lower), JCP -8.7%, SPRD -8.6% (also downgraded to Hold from Buy at Canaccord Genuity), STRA -8.3%, WPRT -6.6%, HTWR -5.9% (light volume), PEGA -5.7%, IO -5.6% (light volume), INN -5.5% (light volume), RNDY -5.3%, STEM -3.6%, JWN -3.2%, DIS -2.7%, HALO -2.5%, (light volume), INWK -1.8%.
M&A news: PCLN -2.7% (KAYAK to be acquired by Priceline for $40/share) .
Financial related names showing weakness: DB -3.5%, ING -2.2%, SAN -2.1%, BCS -1.8%, HBC -1.1%, UBS -0.7%.
Other news: GDOT -11.6% (light volume, following intraday spike on insider buy), ARRY -10.3% (announces proposed public offering of common stock; size not disclosed), PGRX -9.7% (prices 15 mln shares of its common stock to the public at $1.75 per share), ANTH -9.5% (entered into an At Market Issuance Sales Agreement), PVR -5.8% (announces public offering of 6,500,000 common units), EXPE -3.3% and TRIP -2% (following KYAK/PCLN news), MRC -3% (upsized 20 mln share public offering of common stock by selling stockholder at $22.00 per share), TUMI -1.9% (announces pricing of secondary offering of common stock), PSLV -1.6% (announces follow-on offering of trust units), NVO -0.8% (insulin degludec and insulin degludec/insulin aspart receive positive vote for approval from FDA Advisory Committee), .
Analyst comments: CSCO -1.1% (downgraded to Neutral at JP Morgan), CTXS -0.3% (downgraded to Equal Weight from Overweight at Barclays) 08:25 SCANX Gapping down
Market Data 
Markets 
AI
